JP2007517071A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007517071A5 JP2007517071A5 JP2006549289A JP2006549289A JP2007517071A5 JP 2007517071 A5 JP2007517071 A5 JP 2007517071A5 JP 2006549289 A JP2006549289 A JP 2006549289A JP 2006549289 A JP2006549289 A JP 2006549289A JP 2007517071 A5 JP2007517071 A5 JP 2007517071A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- effective amount
- therapeutically effective
- acceptable carrier
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 201000011510 cancer Diseases 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 239000003937 drug carrier Substances 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 239000000556 agonist Substances 0.000 claims 4
- 230000000394 mitotic effect Effects 0.000 claims 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims 2
- 101710149643 Integrin alpha-IIb Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 108010016731 PPAR gamma Proteins 0.000 claims 2
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 claims 2
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000003474 anti-emetic effect Effects 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 229940125683 antiemetic agent Drugs 0.000 claims 2
- 239000002111 antiemetic agent Substances 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 230000012820 cell cycle checkpoint Effects 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 239000000824 cytostatic agent Substances 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000002834 estrogen receptor modulator Substances 0.000 claims 2
- 239000004030 hiv protease inhibitor Substances 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 239000000411 inducer Substances 0.000 claims 2
- 230000036457 multidrug resistance Effects 0.000 claims 2
- 208000004235 neutropenia Diseases 0.000 claims 2
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 claims 2
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 102000027483 retinoid hormone receptors Human genes 0.000 claims 2
- 108091008679 retinoid hormone receptors Proteins 0.000 claims 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 2
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000007755 survival signaling Effects 0.000 claims 2
- 239000003558 transferase inhibitor Substances 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 229940123877 Aurora kinase inhibitor Drugs 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 1
- 102000010638 Kinesin Human genes 0.000 claims 1
- 108010063296 Kinesin Proteins 0.000 claims 1
- 229940124179 Kinesin inhibitor Drugs 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 229940121742 Serine/threonine kinase inhibitor Drugs 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229940123468 Transferase inhibitor Drugs 0.000 claims 1
- 239000003719 aurora kinase inhibitor Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 201000004962 larynx cancer Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 201000007275 lymphatic system cancer Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 229940075993 receptor modulator Drugs 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 230000020347 spindle assembly Effects 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical group C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 claims 1
- 229960003425 tirofiban Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
Claims (18)
- 処置を必要とする哺乳動物におけるがん治療又は予防のための医薬組成物であって、治療上有効量の請求項１化合物と医薬的に許容できる担体を含むことを特徴とする、前記組成物。
- 処置を必要とする哺乳動物におけるがん治療又は予防のための医薬組成物であって、治療上有効量の請求項３記載の化合物と医薬的に許容できる担体を含むことを特徴とする、前記組成物。
- がんが、脳、泌尿生殖路、リンパ系、胃、喉頭、及び肺のがんから選択される、請求項８に記載の組成物。
- がんが、組織球性リンパ腫、肺腺がん、肺小細胞がん、すい臓がん、グリア芽腫、及び乳がんから選択される、請求項８に記載の組成物。
- 治療上有効量の請求項１の化合物と医薬的に許容できる担体を含むことを特徴とする、がん治療のための医薬組成物であって、放射線療法と併用される前記組成物。
- エストロゲン受容体調節剤、アンドロゲン受容体調節剤、レチノイド受容体調節剤、細胞傷害性/細胞増殖抑制剤、抗増殖性物質、プレニルタンパク質トランスフェラーゼ阻害剤、HMG-CoA還元酵素阻害剤、HIVプロテアーゼ阻害剤、逆転写酵素阻害剤、血管新生阻害剤、PPAR-γ作用薬、PPAR-δ作用薬、固有多剤耐性阻害剤、制吐剤、貧血治療に有用な薬剤、好中球減少症治療に有用な薬剤、免疫刺激剤、細胞増殖と生存シグナリングの阻害剤、細胞周期チェックポイントを妨げる薬剤、及びアポトーシス誘導物質、から選択される化合物と一緒に、治療上有効量の請求項１の化合物と医薬的に許容できる担体を含むことを特徴とする、がん治療又は予防のための医薬組成物。
- 放射線療法、並びに、エストロゲン受容体調節剤、アンドロゲン受容体調節剤、レチノイド受容体調節剤、細胞傷害性/細胞増殖抑制剤、抗増殖性物質、プレニルタンパク質トランスフェラーゼ阻害剤、HMG-CoA還元酵素阻害剤、HIVプロテアーゼ阻害剤、逆転写酵素阻害剤、血管新生阻害剤、PPAR-γ作用薬、PPAR-δ作用薬、固有多剤耐性阻害剤、制吐剤、貧血治療に有用な薬剤、好中球減少症治療に有用な薬剤、免疫刺激剤、細胞増殖と生存シグナリングの阻害剤、細胞周期チェックポイントを妨げる薬剤、及びアポトーシス誘導物質、から選択される化合物と一緒に、治療上有効量の請求項１化合物と医薬的に許容できる担体を含むことを特徴とする、がん治療のための医薬組成物。
- 医薬的に許容できる担体と一緒に、治療上有効量の請求項１の化合物、及びパクリタクセル又はトラスツズマブを含むことを特徴とする、がん治療又は予防のための医薬組成物。
- 医薬的に許容できる担体と一緒に、治療上有効量の請求項１の化合物、及びGPIIb/IIIa拮抗薬を含むことを特徴とする、がん治療又は予防のための医薬組成物。
- GPIIb/IIIa拮抗薬が、チロフィバンである、請求項２５記載の組成物。
- COX-2阻害剤と一緒に、治療上有効量の請求項１の化合物と医薬的に許容できる担体を含むことを特徴とする、がん治療又は予防のための医薬組成物。
- プロテソーム阻害剤と一緒に、治療上有効量の請求項１の化合物と医薬的に許容できる担体を含むことを特徴とする、がん治療又は予防のための医薬組成物。
- オーロラキナーゼ阻害剤と一緒に、治療上有効量の請求項１の化合物と医薬的に許容できる担体を含むことを特徴とする、がん治療又は予防のための医薬組成物。
- ラフキナーゼ阻害剤と一緒に、治療上有効量の請求項１の化合物と医薬的に許容できる担体を含むことを特徴とする、がん治療又は予防のための医薬組成物。
- セリン/トレオニンキナーゼ阻害剤と一緒に、治療上有効量の請求項１の化合物と医薬的に許容できる担体を含むことを特徴とする、がん治療又は予防のための医薬組成物。
- KSPでない有糸分裂キネシン阻害剤と一緒に、治療上有効量の請求項１の化合物と医薬的に許容できる担体を含むことを特徴とする、がん治療又は予防のための医薬組成物。
- 治療上有効量の請求項１の化合物と医薬的に許容できる担体を含むことを特徴とする、有糸分裂紡錘体形成を調整するための医薬組成物。
- 治療上有効量の請求項1の化合物と医薬的に許容できる担体を含むことを特徴とする、有糸分裂なキネシンKSPを阻害するための医薬組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53137203P | 2003-12-19 | 2003-12-19 | |
| PCT/US2004/042070 WO2005065183A2 (en) | 2003-12-19 | 2004-12-15 | Mitotic kinesin inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007517071A JP2007517071A (ja) | 2007-06-28 |
| JP2007517071A5 true JP2007517071A5 (ja) | 2008-02-21 |
Family
ID=34748759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006549289A Withdrawn JP2007517071A (ja) | 2003-12-19 | 2004-12-15 | 有糸分裂キネシン阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070060601A1 (ja) |
| EP (1) | EP1696927A4 (ja) |
| JP (1) | JP2007517071A (ja) |
| CN (1) | CN1893951A (ja) |
| AU (1) | AU2004311737A1 (ja) |
| CA (1) | CA2549641A1 (ja) |
| WO (1) | WO2005065183A2 (ja) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005108376A1 (en) * | 2004-05-06 | 2005-11-17 | Smithkline Beecham Corporation | Calcilytic compounds |
| EP2332527A3 (en) | 2004-10-20 | 2011-11-16 | Resverlogix Corp. | Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases |
| KR101431279B1 (ko) | 2005-07-29 | 2014-08-20 | 리스버로직스 코퍼레이션 | 복합 질환의 예방 및 치료용 약학적 조성물 및 삽입가능한의료 장치에 의한 이의 전달 |
| AU2006318275A1 (en) * | 2005-11-22 | 2007-05-31 | Smithkline Beecham Corporation | Calcilytic compounds |
| AU2007303846B2 (en) * | 2006-10-04 | 2011-03-10 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists |
| PL2118074T3 (pl) | 2007-02-01 | 2014-06-30 | Resverlogix Corp | Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego |
| CN101531638B (zh) * | 2008-03-13 | 2011-12-28 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
| NZ586440A (en) | 2008-06-26 | 2011-07-29 | Resverlogix Corp | Methods of preparing quinazolinone derivatives |
| CN101628913B (zh) * | 2008-07-18 | 2013-01-23 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
| ES2463097T3 (es) | 2009-01-08 | 2014-05-27 | Resverlogix Corp. | Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares |
| US9238640B2 (en) | 2009-03-18 | 2016-01-19 | Resverlogix Corp. | Anti-inflammatory agents |
| NZ596117A (en) | 2009-04-22 | 2014-10-31 | Resverlogix Corp | Novel anti-inflammatory agents |
| HUE044986T2 (hu) | 2011-11-01 | 2019-11-28 | Resverlogix Corp | Orális, azonnali felszabadulású készítmények szubsztituált kinazolinonokhoz |
| WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| KR20150096794A (ko) | 2012-12-21 | 2015-08-25 | 제니쓰 에피제네틱스 코포레이션 | 브로모도메인 저해제로서의 신규한 헤테로사이클릭 화합물 |
| CN114984016A (zh) | 2015-03-13 | 2022-09-02 | 雷斯韦洛吉克斯公司 | 用于治疗补体相关疾病之组合物及治疗方法 |
| CN107417628A (zh) * | 2017-06-28 | 2017-12-01 | 中国人民解放军军事医学科学院毒物药物研究所 | 二芳基喹唑啉酮类化合物、其制备方法及其医药用途以及包含该类化合物的药物组合物 |
| CN110041273B (zh) * | 2019-05-29 | 2020-10-20 | 中国人民解放军军事科学院军事医学研究院 | 2-(2-氯-4-甲基苯基)喹唑啉-4(3h)-酮类化合物及其医药用途 |
| CN110041272B (zh) * | 2019-05-29 | 2020-10-30 | 中国人民解放军军事科学院军事医学研究院 | 2-(2-氯苯基)喹唑啉-4(3h)-酮类衍生物及其制备方法和用途 |
| BR112023009531A2 (pt) | 2020-11-18 | 2023-10-03 | Deciphera Pharmaceuticals Llc | Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3257397A (en) * | 1963-07-26 | 1966-06-21 | Rexall Drug Chemical | Substituted 2, 3-dihydro-4(1h)-quinazolinones |
| US3231572A (en) * | 1963-08-05 | 1966-01-25 | Miles Lab | 3-substituted-4-quinazolones |
| DE1670416A1 (de) * | 1966-12-30 | 1971-02-11 | Chem Fab Von Heyden Gmbh Muenc | Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten |
| US3463778A (en) * | 1967-01-13 | 1969-08-26 | Squibb & Sons Inc | Substituted 2,3-dihydro-4(1h)-quinazolinones |
| DE3166627D1 (en) * | 1980-12-12 | 1984-11-15 | Thomae Gmbh Dr K | Pyrimidones, their preparation and medicines containing them |
| DE3717034A1 (de) * | 1987-05-21 | 1988-12-08 | Basf Ag | Photopolymerisierbare aufzeichnungsmaterialien sowie photoresistschichten und flachdruckplatten auf basis dieser aufzeichnungsmaterialien, sowie neue chinazolon-4-verbindungen |
| US5925642A (en) * | 1995-11-24 | 1999-07-20 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pyridopyrimidines |
| US5948775A (en) * | 1997-03-19 | 1999-09-07 | American Home Products Corporation | 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones |
| US6545004B1 (en) * | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| US6479499B1 (en) * | 2000-06-28 | 2002-11-12 | National Science Council | 2-phenyl-4-quinazolinone compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions |
| AU2003265242A1 (en) * | 2002-05-23 | 2003-12-22 | Cytokinetics, Inc. | Compounds, compositions, and methods |
-
2004
- 2004-12-15 CN CNA2004800376917A patent/CN1893951A/zh active Pending
- 2004-12-15 JP JP2006549289A patent/JP2007517071A/ja not_active Withdrawn
- 2004-12-15 WO PCT/US2004/042070 patent/WO2005065183A2/en active Application Filing
- 2004-12-15 EP EP04814275A patent/EP1696927A4/en not_active Withdrawn
- 2004-12-15 AU AU2004311737A patent/AU2004311737A1/en not_active Abandoned
- 2004-12-15 US US10/582,823 patent/US20070060601A1/en not_active Abandoned
- 2004-12-15 CA CA002549641A patent/CA2549641A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007517071A5 (ja) | ||
| Antoszczak et al. | Old wine in new bottles: Drug repurposing in oncology | |
| Piperdi et al. | Bortezomib: understanding the mechanism of action | |
| JP2008527038A5 (ja) | ||
| JP2008527039A5 (ja) | ||
| Chen et al. | Autophagy is a therapeutic target in anticancer drug resistance | |
| Milano et al. | The proteasome: a worthwhile target for the treatment of solid tumours? | |
| JP2008527041A5 (ja) | ||
| Loong et al. | Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma | |
| Maris et al. | Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program | |
| Mirzaei et al. | ABC-transporter blockage mediated by xanthotoxin and bergapten is the major pathway for chemosensitization of multidrug-resistant cancer cells | |
| RU2018102078A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| Abdelaleem et al. | Prospects for repurposing CNS drugs for cancer treatment | |
| Serafin et al. | Drug repositioning in oncology | |
| US20060235006A1 (en) | Combinations, methods and compositions for treating cancer | |
| PT1307197E (pt) | Composicoes para o tratamento do cancro compreendendo um inibidor de topoisomerase e talidomida | |
| JP2009510171A5 (ja) | ||
| NZ621972A (en) | Nanoparticle comprising rapamycin and albumin as anticancer agent | |
| Jin et al. | Curaxin CBL0137 exerts anticancer activity via diverse mechanisms | |
| Nepali et al. | Early investigational tubulin inhibitors as novel cancer therapeutics | |
| NZ588913A (en) | Liver cancer drug | |
| McLaughlin et al. | Modulation of the opioid growth factor ([Met5]‐enkephalin)–opioid growth factor receptor axis: Novel therapies for squamous cell carcinoma of the head and neck | |
| JP2009539994A5 (ja) | ||
| FR2869540B1 (fr) | Compositions pharmaceutiques contenant des derives de b-carboline, et leur utilisation pour le traitement des cancers | |
| Srikumar et al. | Potential use of flavopiridol in treatment of chronic diseases |